OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2023
(3)
2024
(2)
2025
(1)
2022
(1)
2021
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Spinal neuron diversity scales exponentially with swim-to-limb transformation during frog metamorphosis.
Not available
S-EPMC11430061
|
biostudies-literature
Cite
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Not available
S-EPMC10728430
|
biostudies-literature
Cite
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Not available
S-EPMC11001930
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10156147
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets